Adynxx, Inc. (ADYX) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en San Francisco, CA, United States. El CEO actual es Richard Orr.
ADYX tiene fecha de IPO 1998-12-18, 6 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $581.00.
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
